- Patent Title: Oxybutynin-xanomeline transdermal therapeutic system combinations
-
Application No.: US15556197Application Date: 2016-03-04
-
Publication No.: US10195187B2Publication Date: 2019-02-05
- Inventor: Thomas N. Chase , Kathleen E. Clarence-Smith
- Applicant: Chase Pharmaceuticals Corporation
- Applicant Address: US NJ Madison
- Assignee: Chase Pharmaceuticals Corporation
- Current Assignee: Chase Pharmaceuticals Corporation
- Current Assignee Address: US NJ Madison
- Agent Roy Isaac
- International Application: PCT/US2016/020879 WO 20160304
- International Announcement: WO2016/144749 WO 20160915
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61K31/216 ; A61K9/06 ; A61K9/70 ; A61P25/28
Abstract:
Transdermal therapeutic system and method of using the same for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The transdermal therapeutic system comprises oxybutynin in combination with a cholinergic receptor agonist (CRA) such as xanomeline.
Public/Granted literature
- US20180050023A1 OXYBUTYNIN-XANOMELINE TRANSDERMAL THERAPEUTIC SYSTEM COMBINATIONS Public/Granted day:2018-02-22
Information query
IPC分类:
